Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumor Malignancy × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 9 Recurrence 5 Sarcoma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2 Carcinoma, Non-Small-Cell Lung 2 Waldenstrom Macroglobulinemia 1 Vascular Neoplasms 1 Triple Negative Breast Neoplasms 1 Solitary Fibrous Tumors 1 Solid Tumor Malignancy 1 Smooth Muscle Tumor 1 Sarcoma, Clear Cell 1 Recurrent Squamous Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neurofibrosarcoma 1 Nerve Sheath Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms, Adipose Tissue 1 Neoplasm Metastasis 1 Myoepithelioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Liposarcoma, Myxoid 1 Liposarcoma 1

Interventions

selinexor 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Hackensack Meridian Health

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡